Frontier Medicines
↗South San Francisco, USA
Frontier Medicines is a clinical-stage precision medicine company focused on developing therapies for traditionally 'undruggable' disease-causing proteins. The company utilizes its proprietary Frontier™ Platform, which integrates chemoproteomics, covalent drug discovery, and machine learning to identify and target new binding pockets (hotspots) on proteins, making them accessible to small-molecule intervention.
The company's lead program, FMC-376, is a first-in-class dual inhibitor of both the active (ON) and inactive (OFF) states of KRAS G12C, designed to overcome resistance mechanisms seen in earlier generation inhibitors. Frontier is also advancing a pipeline of wholly-owned and partnered programs in oncology and immunology, including a significant multi-year collaboration with AbbVie to discover and develop novel E3 ligase degraders and other difficult-to-drug targets.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Precision Oncology & Chemoproteomics
SIZE & FINANCIALS
Employees:51-200
Revenue:$10M-$50M
Founded:2018
Ownership:private
Status:operating
FUNDING
Stage:Series C
Total Raised:$255.5M
Investors:Deerfield Management Company, Droia Ventures, Galapagos NV, MPM Capital, RA Capital Management, DCVC Bio, ArrowMark Partners, Deep Track Capital, Driehaus Capital Management, Sphera Funds Management
PIPELINE
Stage:Phase 1/2
Lead Drug Stage:Phase 1/2
Modalities:Small molecule, Covalent inhibitors, Targeted Protein Degradation (TPD)
Active Trials:1
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:AbbVie: Global strategic collaboration (2020) to discover and develop small molecule therapeutics against E3 ligases and oncology/immunology targets., Galapagos NV: Strategic investment and collaboration context within Series C financing.
COMPETITION
Position:Emerging
Competitors:Kymera Therapeutics, C4 Therapeutics, Arvinas, Nurix Therapeutics, BridgeBio, Amgen (Lumakras), Bristol Myers Squibb (Krazati)
LEADERSHIP
Key Executives:
Chris Varma, Ph.D. - Co-founder, Chairman and CEO
Kevin Webster, Ph.D. - Chief Scientific Officer
Gerardo Ubaghs - Chief Financial Officer
Christo Shalish - SVP and Head of Business Development
Scientific Founders:Daniel K. Nomura, Ph.D. (UC Berkeley), Roberto Zoncu, Ph.D. (UC Berkeley), Chris Varma, Ph.D.
Board Members:Chris Varma, Derek DiRocco (RA Capital), Pamela M. Klein, M.D., Kevin Koch, Ph.D.
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Frontier Medicines. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.